Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Molecular Neurodegeneration
Published in: Molecular Neurodegeneration 1/2009

Open Access 01-12-2009 | Review

Calcium signaling in neurodegeneration

Authors: Philippe Marambaud, Ute Dreses-Werringloer, Valérie Vingtdeux

Published in: Molecular Neurodegeneration | Issue 1/2009

Login to get access

Abstract

Calcium is a key signaling ion involved in many different intracellular and extracellular processes ranging from synaptic activity to cell-cell communication and adhesion. The exact definition at the molecular level of the versatility of this ion has made overwhelming progress in the past several years and has been extensively reviewed. In the brain, calcium is fundamental in the control of synaptic activity and memory formation, a process that leads to the activation of specific calcium-dependent signal transduction pathways and implicates key protein effectors, such as CaMKs, MAPK/ERKs, and CREB. Properly controlled homeostasis of calcium signaling not only supports normal brain physiology but also maintains neuronal integrity and long-term cell survival. Emerging knowledge indicates that calcium homeostasis is not only critical for cell physiology and health, but also, when deregulated, can lead to neurodegeneration via complex and diverse mechanisms involved in selective neuronal impairments and death. The identification of several modulators of calcium homeostasis, such as presenilins and CALHM1, as potential factors involved in the pathogenesis of Alzheimer's disease, provides strong support for a role of calcium in neurodegeneration. These observations represent an important step towards understanding the molecular mechanisms of calcium signaling disturbances observed in different brain diseases such as Alzheimer's, Parkinson's, and Huntington's diseases.
Appendix
Available only for authorised users
Literature
1.
Catterall WA, Few AP: Calcium channel regulation and presynaptic plasticity. Neuron. 2008, 59: 882-901.PubMed
2.
Greer PL, Greenberg ME: From synapse to nucleus: calcium-dependent gene transcription in the control of synapse development and function. Neuron. 2008, 59: 846-860.PubMed
3.
Higley MJ, Sabatini BL: Calcium signaling in dendrites and spines: practical and functional considerations. Neuron. 2008, 59: 902-913.PubMed
4.
Mattson MP: Neurotransmitters in the regulation of neuronal cytoarchitecture. Brain Res. 1988, 472: 179-212.PubMed
5.
Redmond L, Ghosh A: Regulation of dendritic development by calcium signaling. Cell Calcium. 2005, 37: 411-416.PubMed
6.
Berridge MJ, Bootman MD, Roderick HL: Calcium signalling: dynamics, homeostasis and remodelling. Nat Rev Mol Cell Biol. 2003, 4: 517-529.PubMed
7.
LaFerla FM: Calcium dyshomeostasis and intracellular signalling in Alzheimer's disease. Nat Rev Neurosci. 2002, 3: 862-872.PubMed
8.
Bliss TV, Collingridge GL: A synaptic model of memory: long-term potentiation in the hippocampus. Nature. 1993, 361: 31-39.PubMed
9.
Lynch MA: Long-term potentiation and memory. Physiol Rev. 2004, 84: 87-136.PubMed
10.
Malenka RC, Kauer JA, Perkel DJ, Mauk MD, Kelly PT, Nicoll RA, Waxham MN: An essential role for postsynaptic calmodulin and protein kinase activity in long-term potentiation. Nature. 1989, 340: 554-557.PubMed
11.
Malinow R, Madison DV, Tsien RW: Persistent protein kinase activity underlying long-term potentiation. Nature. 1988, 335: 820-824.PubMed
12.
Krug M, Lossner B, Ott T: Anisomycin blocks the late phase of long-term potentiation in the dentate gyrus of freely moving rats. Brain Res Bull. 1984, 13: 39-42.PubMed
13.
Frey U, Krug M, Reymann KG, Matthies H: Anisomycin, an inhibitor of protein synthesis, blocks late phases of LTP phenomena in the hippocampal CA1 region in vitro. Brain Res. 1988, 452: 57-65.PubMed
14.
Fazeli MS, Corbet J, Dunn MJ, Dolphin AC, Bliss TV: Changes in protein synthesis accompanying long-term potentiation in the dentate gyrus in vivo. J Neurosci. 1993, 13: 1346-1353.PubMed
15.
Malenka RC, Kauer JA, Zucker RS, Nicoll RA: Postsynaptic calcium is sufficient for potentiation of hippocampal synaptic transmission. Science. 1988, 242: 81-84.PubMed
16.
Lynch G, Larson J, Kelso S, Barrionuevo G, Schottler F: Intracellular injections of EGTA block induction of hippocampal long-term potentiation. Nature. 1983, 305: 719-721.PubMed
17.
Hirsch JC, Crepel F: Postsynaptic calcium is necessary for the induction of LTP and LTD of monosynaptic EPSPs in prefrontal neurons: an in vitro study in the rat. Synapse. 1992, 10: 173-175.PubMed
18.
Malenka RC, Kauer JA, Perkel DJ, Nicoll RA: The impact of postsynaptic calcium on synaptic transmission–its role in long-term potentiation. Trends Neurosci. 1989, 12: 444-450.PubMed
19.
Malenka RC, Lancaster B, Zucker RS: Temporal limits on the rise in postsynaptic calcium required for the induction of long-term potentiation. Neuron. 1992, 9: 121-128.PubMed
20.
Collingridge GL, Kehl SJ, McLennan H: Excitatory amino acids in synaptic transmission in the Schaffer collateral-commissural pathway of the rat hippocampus. J Physiol. 1983, 334: 33-46.PubMedCentralPubMed
21.
Coan EJ, Collingridge GL: Characterization of an N-methyl-D-aspartate receptor component of synaptic transmission in rat hippocampal slices. Neuroscience. 1987, 22: 1-8.PubMed
22.
Errington ML, Lynch MA, Bliss TV: Long-term potentiation in the dentate gyrus: induction and increased glutamate release are blocked by D(-)aminophosphonovalerate. Neuroscience. 1987, 20: 279-284.PubMed
23.
Maren S: Long-term potentiation in the amygdala: a mechanism for emotional learning and memory. Trends Neurosci. 1999, 22: 561-567.PubMed
24.
Jay TM, Burette F, Laroche S: Plasticity of the hippocampal-prefrontal cortex synapses. J Physiol Paris. 1996, 90: 361-366.PubMed
25.
Morris RG, Anderson E, Lynch GS, Baudry M: Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5. Nature. 1986, 319: 774-776.PubMed
26.
Tsien JZ, Huerta PT, Tonegawa S: The essential role of hippocampal CA1 NMDA receptor-dependent synaptic plasticity in spatial memory. Cell. 1996, 87: 1327-1338.PubMed
27.
Fanselow MS, Kim JJ: Acquisition of contextual Pavlovian fear conditioning is blocked by application of an NMDA receptor antagonist D, L-2-amino-5-phosphonovaleric acid to the basolateral amygdala. Behav Neurosci. 1994, 108: 210-212.PubMed
28.
Lee HJ, Choi JS, Brown TH, Kim JJ: Amygdalar nmda receptors are critical for the expression of multiple conditioned fear responses. J Neurosci. 2001, 21: 4116-4124.PubMed
29.
Grover LM, Teyler TJ: Two components of long-term potentiation induced by different patterns of afferent activation. Nature. 1990, 347: 477-479.PubMed
30.
Raymond CR, Redman SJ: Different calcium sources are narrowly tuned to the induction of different forms of LTP. J Neurophysiol. 2002, 88: 249-255.PubMed
31.
Behnisch T, Reymann KG: Thapsigargin blocks long-term potentiation induced by weak, but not strong tetanisation in rat hippocampal CA1 neurons. Neurosci Lett. 1995, 192: 185-188.PubMed
32.
Harvey J, Collingridge GL: Thapsigargin blocks the induction of long-term potentiation in rat hippocampal slices. Neurosci Lett. 1992, 139: 197-200.PubMed
33.
Wang Y, Wu J, Rowan MJ, Anwyl R: Ryanodine produces a low frequency stimulation-induced NMDA receptor-independent long-term potentiation in the rat dentate gyrus in vitro. J Physiol. 1996, 495 (Pt 3): 755-767.PubMedCentralPubMed
34.
Obenaus A, Mody I, Baimbridge KG: Dantrolene-Na (Dantrium) blocks induction of long-term potentiation in hippocampal slices. Neurosci Lett. 1989, 98: 172-178.PubMed
35.
Wayman GA, Lee YS, Tokumitsu H, Silva A, Soderling TR: Calmodulin-kinases: modulators of neuronal development and plasticity. Neuron. 2008, 59: 914-931.PubMedCentralPubMed
36.
Abel T, Nguyen PV: Regulation of hippocampus-dependent memory by cyclic AMP-dependent protein kinase. Prog Brain Res. 2008, 169: 97-115.PubMedCentralPubMed
37.
Malinow R, Schulman H, Tsien RW: Inhibition of postsynaptic PKC or CaMKII blocks induction but not expression of LTP. Science. 1989, 245: 862-866.PubMed
38.
Saito N, Shirai Y: Protein kinase C gamma (PKC gamma): function of neuron specific isotype. J Biochem. 2002, 132: 683-687.PubMed
39.
Silva AJ, Paylor R, Wehner JM, Tonegawa S: Impaired spatial learning in alpha-calcium-calmodulin kinase II mutant mice. Science. 1992, 257: 206-211.PubMed
40.
Silva AJ, Stevens CF, Tonegawa S, Wang Y: Deficient hippocampal long-term potentiation in alpha-calcium-calmodulin kinase II mutant mice. Science. 1992, 257: 201-206.PubMed
41.
Pettit DL, Perlman S, Malinow R: Potentiated transmission and prevention of further LTP by increased CaMKII activity in postsynaptic hippocampal slice neurons. Science. 1994, 266: 1881-1885.PubMed
42.
Lledo PM, Hjelmstad GO, Mukherji S, Soderling TR, Malenka RC, Nicoll RA: Calcium/calmodulin-dependent kinase II and long-term potentiation enhance synaptic transmission by the same mechanism. Proc Natl Acad Sci USA. 1995, 92: 11175-11179.PubMedCentralPubMed
43.
Barria A, Muller D, Derkach V, Griffith LC, Soderling TR: Regulatory phosphorylation of AMPA-type glutamate receptors by CaM-KII during long-term potentiation. Science. 1997, 276: 2042-2045.PubMed
44.
Roche KW, O'Brien RJ, Mammen AL, Bernhardt J, Huganir RL: Characterization of multiple phosphorylation sites on the AMPA receptor GluR1 subunit. Neuron. 1996, 16: 1179-1188.PubMed
45.
Derkach V, Barria A, Soderling TR: Ca2+/calmodulin-kinase II enhances channel conductance of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate type glutamate receptors. Proc Natl Acad Sci USA. 1999, 96: 3269-3274.PubMedCentralPubMed
46.
Boulton TG, Nye SH, Robbins DJ, Ip NY, Radziejewska E, Morgenbesser SD, DePinho RA, Panayotatos N, Cobb MH, Yancopoulos GD: ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell. 1991, 65: 663-675.PubMed
47.
English JD, Sweatt JD: Activation of p42 mitogen-activated protein kinase in hippocampal long term potentiation. J Biol Chem. 1996, 271: 24329-24332.PubMed
48.
English JD, Sweatt JD: A requirement for the mitogen-activated protein kinase cascade in hippocampal long term potentiation. J Biol Chem. 1997, 272: 19103-19106.PubMed
49.
Bading H, Greenberg ME: Stimulation of protein tyrosine phosphorylation by NMDA receptor activation. Science. 1991, 253: 912-914.PubMed
50.
Mazzucchelli C, Brambilla R: Ras-related and MAPK signalling in neuronal plasticity and memory formation. Cell Mol Life Sci. 2000, 57: 604-611.PubMed
51.
Adams JP, Sweatt JD: Molecular psychology: roles for the ERK MAP kinase cascade in memory. Annu Rev Pharmacol Toxicol. 2002, 42: 135-163.PubMed
52.
Sweatt JD: Mitogen-activated protein kinases in synaptic plasticity and memory. Curr Opin Neurobiol. 2004, 14: 311-317.PubMed
53.
Thomas GM, Huganir RL: MAPK cascade signalling and synaptic plasticity. Nat Rev Neurosci. 2004, 5: 173-183.PubMed
54.
Krapivinsky G, Krapivinsky L, Manasian Y, Ivanov A, Tyzio R, Pellegrino C, Ben-Ari Y, Clapham DE, Medina I: The NMDA receptor is coupled to the ERK pathway by a direct interaction between NR2B and RasGRF1. Neuron. 2003, 40: 775-784.PubMed
55.
Tian X, Gotoh T, Tsuji K, Lo EH, Huang S, Feig LA: Developmentally regulated role for Ras-GRFs in coupling NMDA glutamate receptors to Ras, Erk and CREB. Embo J. 2004, 23: 1567-1575.PubMedCentralPubMed
56.
Chen HJ, Rojas-Soto M, Oguni A, Kennedy MB: A synaptic Ras-GTPase activating protein (p135 SynGAP) inhibited by CaM kinase II. Neuron. 1998, 20: 895-904.PubMed
57.
Roberson ED, English JD, Adams JP, Selcher JC, Kondratick C, Sweatt JD: The mitogen-activated protein kinase cascade couples PKA and PKC to cAMP response element binding protein phosphorylation in area CA1 of hippocampus. J Neurosci. 1999, 19: 4337-4348.PubMed
58.
Mark MD, Liu Y, Wong ST, Hinds TR, Storm DR: Stimulation of neurite outgrowth in PC12 cells by EGF and KCl depolarization: a Ca(2+)-independent phenomenon. J Cell Biol. 1995, 130: 701-710.PubMed
59.
Yao H, Labudda K, Rim C, Capodieci P, Loda M, Stork PJ: Cyclic adenosine monophosphate can convert epidermal growth factor into a differentiating factor in neuronal cells. J Biol Chem. 1995, 270: 20748-20753.PubMed
60.
Wang JQ, Fibuch EE, Mao L: Regulation of mitogen-activated protein kinases by glutamate receptors. J Neurochem. 2007, 100: 1-11.PubMed
61.
Fiore RS, Bayer VE, Pelech SL, Posada J, Cooper JA, Baraban JM: p42 mitogen-activated protein kinase in brain: prominent localization in neuronal cell bodies and dendrites. Neuroscience. 1993, 55: 463-472.PubMed
62.
Atkins CM, Selcher JC, Petraitis JJ, Trzaskos JM, Sweatt JD: The MAPK cascade is required for mammalian associative learning. Nat Neurosci. 1998, 1: 602-609.PubMed
63.
Selcher JC, Nekrasova T, Paylor R, Landreth GE, Sweatt JD: Mice lacking the ERK1 isoform of MAP kinase are unimpaired in emotional learning. Learn Mem. 2001, 8: 11-19.PubMedCentralPubMed
64.
Aouadi M, Binetruy B, Caron L, Le Marchand-Brustel Y, Bost F: Role of MAPKs in development and differentiation: lessons from knockout mice. Biochimie. 2006, 88: 1091-1098.PubMed
65.
Mazzucchelli C, Vantaggiato C, Ciamei A, Fasano S, Pakhotin P, Krezel W, Welzl H, Wolfer DP, Pages G, Valverde O, Marowsky A, Porrazzo A, Orban PC, Maldonado R, Ehrengruber MU, Cestari V, Lipp HP, Chapman PF, Pouyssegur J, Brambilla R: Knockout of ERK1 MAP kinase enhances synaptic plasticity in the striatum and facilitates striatal-mediated learning and memory. Neuron. 2002, 34: 807-820.PubMed
66.
Samuels IS, Karlo JC, Faruzzi AN, Pickering K, Herrup K, Sweatt JD, Saitta SC, Landreth GE: Deletion of ERK2 mitogen-activated protein kinase identifies its key roles in cortical neurogenesis and cognitive function. J Neurosci. 2008, 28: 6983-6995.PubMedCentralPubMed
67.
Tsokas P, Ma T, Iyengar R, Landau EM, Blitzer RD: Mitogen-activated protein kinase upregulates the dendritic translation machinery in long-term potentiation by controlling the mammalian target of rapamycin pathway. J Neurosci. 2007, 27: 5885-5894.PubMed
68.
Pittenger C, Kandel ER: In search of general mechanisms for long-lasting plasticity: Aplysia and the hippocampus. Philos Trans R Soc Lond B Biol Sci. 2003, 358: 757-763.PubMedCentralPubMed
69.
Dash PK, Hochner B, Kandel ER: Injection of the cAMP-responsive element into the nucleus of Aplysia sensory neurons blocks long-term facilitation. Nature. 1990, 345: 718-721.PubMed
70.
Alberini CM, Ghirardi M, Metz R, Kandel ER: C/EBP is an immediate-early gene required for the consolidation of long-term facilitation in Aplysia. Cell. 1994, 76: 1099-1114.PubMed
71.
Bartsch D, Ghirardi M, Skehel PA, Karl KA, Herder SP, Chen M, Bailey CH, Kandel ER: Aplysia CREB2 represses long-term facilitation: relief of repression converts transient facilitation into long-term functional and structural change. Cell. 1995, 83: 979-992.PubMed
72.
Bartsch D, Casadio A, Karl KA, Serodio P, Kandel ER: CREB1 encodes a nuclear activator, a repressor, and a cytoplasmic modulator that form a regulatory unit critical for long-term facilitation. Cell. 1998, 95: 211-223.PubMed
73.
Kaang BK, Kandel ER, Grant SG: Activation of cAMP-responsive genes by stimuli that produce long-term facilitation in Aplysia sensory neurons. Neuron. 1993, 10: 427-435.PubMed
74.
Yin JC, Wallach JS, Del Vecchio M, Wilder EL, Zhou H, Quinn WG, Tully T: Induction of a dominant negative CREB transgene specifically blocks long-term memory in Drosophila. Cell. 1994, 79: 49-58.PubMed
75.
Yin JC, Del Vecchio M, Zhou H, Tully T: CREB as a memory modulator: induced expression of a dCREB2 activator isoform enhances long-term memory in Drosophila. Cell. 1995, 81: 107-115.PubMed
76.
Bourtchuladze R, Frenguelli B, Blendy J, Cioffi D, Schutz G, Silva AJ: Deficient long-term memory in mice with a targeted mutation of the cAMP-responsive element-binding protein. Cell. 1994, 79: 59-68.PubMed
77.
Kogan JH, Frankland PW, Blendy JA, Coblentz J, Marowitz Z, Schutz G, Silva AJ: Spaced training induces normal long-term memory in CREB mutant mice. Curr Biol. 1997, 7: 1-11.PubMed
78.
Guzowski JF, McGaugh JL: Antisense oligodeoxynucleotide-mediated disruption of hippocampal cAMP response element binding protein levels impairs consolidation of memory for water maze training. Proc Natl Acad Sci USA. 1997, 94: 2693-2698.PubMedCentralPubMed
79.
Chrivia JC, Kwok RP, Lamb N, Hagiwara M, Montminy MR, Goodman RH: Phosphorylated CREB binds specifically to the nuclear protein CBP. Nature. 1993, 365: 855-859.PubMed
80.
Kwok RP, Lundblad JR, Chrivia JC, Richards JP, Bachinger HP, Brennan RG, Roberts SG, Green MR, Goodman RH: Nuclear protein CBP is a coactivator for the transcription factor CREB. Nature. 1994, 370: 223-226.PubMed
81.
Anderson KA, Means AR: Defective signaling in a subpopulation of CD4(+) T cells in the absence of Ca(2+)/calmodulin-dependent protein kinase IV. Mol Cell Biol. 2002, 22: 23-29.PubMedCentralPubMed
82.
Ho N, Liauw JA, Blaeser F, Wei F, Hanissian S, Muglia LM, Wozniak DF, Nardi A, Arvin KL, Holtzman DM, Linden DJ, Zhuo M, Muglia LJ, Chatila TA: Impaired synaptic plasticity and cAMP response element-binding protein activation in Ca2+/calmodulin-dependent protein kinase type IV/Gr-deficient mice. J Neurosci. 2000, 20: 6459-6472.PubMed
83.
Ribar TJ, Rodriguiz RM, Khiroug L, Wetsel WC, Augustine GJ, Means AR: Cerebellar defects in Ca2+/calmodulin kinase IV-deficient mice. J Neurosci. 2000, 20: RC107-PubMed
84.
Impey S, Obrietan K, Wong ST, Poser S, Yano S, Wayman G, Deloulme JC, Chan G, Storm DR: Cross talk between ERK and PKA is required for Ca2+ stimulation of CREB-dependent transcription and ERK nuclear translocation. Neuron. 1998, 21: 869-883.PubMed
85.
Davis S, Vanhoutte P, Pages C, Caboche J, Laroche S: The MAPK/ERK cascade targets both Elk-1 and cAMP response element-binding protein to control long-term potentiation-dependent gene expression in the dentate gyrus in vivo. J Neurosci. 2000, 20: 4563-4572.PubMed
86.
Dolmetsch RE, Pajvani U, Fife K, Spotts JM, Greenberg ME: Signaling to the nucleus by an L-type calcium channel-calmodulin complex through the MAP kinase pathway. Science. 2001, 294: 333-339.PubMed
87.
Sweatt JD: The neuronal MAP kinase cascade: a biochemical signal integration system subserving synaptic plasticity and memory. J Neurochem. 2001, 76: 1-10.PubMed
88.
Deak M, Clifton AD, Lucocq LM, Alessi DR: Mitogen- and stress-activated protein kinase-1 (MSK1) is directly activated by MAPK and SAPK2/p38, and may mediate activation of CREB. Embo J. 1998, 17: 4426-4441.PubMedCentralPubMed
89.
Wiggin GR, Soloaga A, Foster JM, Murray-Tait V, Cohen P, Arthur JS: MSK1 and MSK2 are required for the mitogen- and stress-induced phosphorylation of CREB and ATF1 in fibroblasts. Mol Cell Biol. 2002, 22: 2871-2881.PubMedCentralPubMed
90.
Dalby KN, Morrice N, Caudwell FB, Avruch J, Cohen P: Identification of regulatory phosphorylation sites in mitogen-activated protein kinase (MAPK)-activated protein kinase-1a/p90rsk that are inducible by MAPK. J Biol Chem. 1998, 273: 1496-1505.PubMed
91.
Xing J, Ginty DD, Greenberg ME: Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase. Science. 1996, 273: 959-963.PubMed
92.
Chwang WB, Arthur JS, Schumacher A, Sweatt JD: The nuclear kinase mitogen- and stress-activated protein kinase 1 regulates hippocampal chromatin remodeling in memory formation. J Neurosci. 2007, 27: 12732-12742.PubMed
93.
Sindreu CB, Scheiner ZS, Storm DR: Ca2+ -stimulated adenylyl cyclases regulate ERK-dependent activation of MSK1 during fear conditioning. Neuron. 2007, 53: 79-89.PubMedCentralPubMed
94.
Wu GY, Deisseroth K, Tsien RW: Activity-dependent CREB phosphorylation: convergence of a fast, sensitive calmodulin kinase pathway and a slow, less sensitive mitogen-activated protein kinase pathway. Proc Natl Acad Sci USA. 2001, 98: 2808-2813.PubMedCentralPubMed
95.
Bito H, Deisseroth K, Tsien RW: CREB phosphorylation and dephosphorylation: a Ca(2+)- and stimulus duration-dependent switch for hippocampal gene expression. Cell. 1996, 87: 1203-1214.PubMed
96.
97.
Selkoe DJ: Alzheimer's disease: genes, proteins, and therapy. Physiol Rev. 2001, 81: 741-766.PubMed
98.
Bezprozvanny I, Mattson MP: Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease. Trends Neurosci. 2008, 31: 454-463.PubMedCentralPubMed
99.
Green KN, LaFerla FM: Linking calcium to Abeta and Alzheimer's disease. Neuron. 2008, 59: 190-194.PubMed
100.
Mattson MP: Calcium and neurodegeneration. Aging Cell. 2007, 6: 337-350.PubMed
101.
Thomas B, Beal MF: Parkinson's disease. Hum Mol Genet. 2007, 16 (Spec No 2): R183-194.PubMed
102.
Hallett PJ, Standaert DG: Rationale for and use of NMDA receptor antagonists in Parkinson's disease. Pharmacol Ther. 2004, 102: 155-174.PubMed
103.
Surmeier DJ: Calcium, ageing, and neuronal vulnerability in Parkinson's disease. Lancet Neurol. 2007, 6: 933-938.PubMed
104.
Ramaswamy S, Shannon KM, Kordower JH: Huntington's disease: pathological mechanisms and therapeutic strategies. Cell Transplant. 2007, 16: 301-312.PubMed
105.
Nakamura K, Aminoff MJ: Huntington's disease: clinical characteristics, pathogenesis and therapies. Drugs Today (Barc). 2007, 43: 97-116.
106.
Fan MM, Raymond LA: N-methyl-D-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease. Prog Neurobiol. 2007, 81: 272-293.PubMed
107.
Bezprozvanny I: Inositol 1,4,5-tripshosphate receptor, calcium signalling and Huntington's disease. Subcell Biochem. 2007, 45: 323-335.PubMed
108.
Rowland LP, Shneider NA: Amyotrophic lateral sclerosis. N Engl J Med. 2001, 344: 1688-1700.PubMed
109.
Strong MJ, Kesavapany S, Pant HC: The pathobiology of amyotrophic lateral sclerosis: a proteinopathy?. J Neuropathol Exp Neurol. 2005, 64: 649-664.PubMed
110.
Alexianu ME, Ho BK, Mohamed AH, La Bella V, Smith RG, Appel SH: The role of calcium-binding proteins in selective motoneuron vulnerability in amyotrophic lateral sclerosis. Ann Neurol. 1994, 36: 846-858.PubMed
111.
von Lewinski F, Keller BU: Ca2+, mitochondria and selective motoneuron vulnerability: implications for ALS. Trends Neurosci. 2005, 28: 494-500.PubMed
112.
Wojda U, Salinska E, Kuznicki J: Calcium ions in neuronal degeneration. IUBMB Life. 2008, 60: 575-590.PubMed
113.
Beers DR, Ho BK, Siklos L, Alexianu ME, Mosier DR, Mohamed AH, Otsuka Y, Kozovska ME, McAlhany RE, Smith RG, Appel SH: Parvalbumin overexpression alters immune-mediated increases in intracellular calcium, and delays disease onset in a transgenic model of familial amyotrophic lateral sclerosis. J Neurochem. 2001, 79: 499-509.PubMed
114.
Iacopino AM, Christakos S: Corticosterone regulates calbindin-D28k mRNA and protein levels in rat hippocampus. J Biol Chem. 1990, 265: 10177-10180.PubMed
115.
McLachlan DR, Wong L, Bergeron C, Baimbridge KG: Calmodulin and calbindin D28K in Alzheimer disease. Alzheimer Dis Assoc Disord. 1987, 1: 171-179.PubMed
116.
Ichimiya Y, Emson PC, Mountjoy CQ, Lawson DE, Heizmann CW: Loss of calbindin-28K immunoreactive neurones from the cortex in Alzheimer-type dementia. Brain Res. 1988, 475: 156-159.PubMed
117.
Seto-Ohshima A, Emson PC, Lawson E, Mountjoy CQ, Carrasco LH: Loss of matrix calcium-binding protein-containing neurons in Huntington's disease. Lancet. 1988, 1: 1252-1255.PubMed
118.
Sattler R, Tymianski M: Molecular mechanisms of calcium-dependent excitotoxicity. J Mol Med. 2000, 78: 3-13.PubMed
119.
Carriedo SG, Yin HZ, Weiss JH: Motor neurons are selectively vulnerable to AMPA/kainate receptor-mediated injury in vitro. J Neurosci. 1996, 16: 4069-4079.PubMed
120.
Williams TL, Day NC, Ince PG, Kamboj RK, Shaw PJ: Calcium-permeable alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors: a molecular determinant of selective vulnerability in amyotrophic lateral sclerosis. Ann Neurol. 1997, 42: 200-207.PubMed
121.
Takuma H, Kwak S, Yoshizawa T, Kanazawa I: Reduction of GluR2 RNA editing, a molecular change that increases calcium influx through AMPA receptors, selective in the spinal ventral gray of patients with amyotrophic lateral sclerosis. Ann Neurol. 1999, 46: 806-815.PubMed
122.
Kruman II, Pedersen WA, Springer JE, Mattson MP: ALS-linked Cu/Zn-SOD mutation increases vulnerability of motor neurons to excitotoxicity by a mechanism involving increased oxidative stress and perturbed calcium homeostasis. Exp Neurol. 1999, 160: 28-39.PubMed
123.
Sun Y, Savanenin A, Reddy PH, Liu YF: Polyglutamine-expanded huntingtin promotes sensitization of N-methyl-D-aspartate receptors via post-synaptic density 95. J Biol Chem. 2001, 276: 24713-24718.PubMed
124.
Blandini F, Porter RH, Greenamyre JT: Glutamate and Parkinson's disease. Mol Neurobiol. 1996, 12: 73-94.PubMed
125.
Konieczny J, Ossowska K, Wolfarth S, Pilc A: LY35 a group II metabotropic glutamate receptor agonist with potential antiparkinsonian properties in rats. Naunyn Schmiedebergs Arch Pharmacol. 1998, 358 (4): 500-502.PubMed
126.
Dawson L, Chadha A, Megalou M, Duty S: The group II metabotropic glutamate receptor agonist, DCG-IV, alleviates akinesia following intranigral or intraventricular administration in the reserpine-treated rat. Br J Pharmacol. 2000, 129: 541-546.PubMedCentralPubMed
127.
Murray TK, Messenger MJ, Ward MA, Woodhouse S, Osborne DJ, Duty S, O'Neill MJ: Evaluation of the mGluR2/3 agonist LY379268 in rodent models of Parkinson's disease. Pharmacol Biochem Behav. 2002, 73: 455-466.PubMed
128.
Bonsi P, Cuomo D, Picconi B, Sciamanna G, Tscherter A, Tolu M, Bernardi G, Calabresi P, Pisani A: Striatal metabotropic glutamate receptors as a target for pharmacotherapy in Parkinson's disease. Amino Acids. 2007, 32: 189-195.PubMed
129.
Golde TE: The Abeta hypothesis: leading us to rationally-designed therapeutic strategies for the treatment or prevention of Alzheimer disease. Brain Pathol. 2005, 15: 84-87.PubMed
130.
Mattson MP, Cheng B, Davis D, Bryant K, Lieberburg I, Rydel RE: beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci. 1992, 12: 376-389.PubMed
131.
Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL: Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci. 2007, 27: 2866-2875.PubMed
132.
Sze C, Bi H, Kleinschmidt-DeMasters BK, Filley CM, Martin LJ: N-Methyl-D-aspartate receptor subunit proteins and their phosphorylation status are altered selectively in Alzheimer's disease. J Neurol Sci. 2001, 182: 151-159.PubMed
133.
Lipton SA: The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism. Curr Alzheimer Res. 2005, 2: 155-165.PubMed
134.
Appel SH, Smith RG, Alexianu MF, Engelhardt JI, Stefani E: Autoimmunity as an etiological factor in sporadic amyotrophic lateral sclerosis. Adv Neurol. 1995, 68: 47-57.PubMed
135.
Delbono O, Garcia J, Appel SH, Stefani E: IgG from amyotrophic lateral sclerosis affects tubular calcium channels of skeletal muscle. Am J Physiol. 1991, 260: C1347-1351.PubMed
136.
Delbono O, Magnelli V, Sawada T, Smith RG, Appel SH, Stefani E: Fab fragments from amyotrophic lateral sclerosis IgG affect calcium channels of skeletal muscle. Am J Physiol. 1993, 264: C537-543.PubMed
137.
Engelhardt JI, Siklos L, Komuves L, Smith RG, Appel SH: Antibodies to calcium channels from ALS patients passively transferred to mice selectively increase intracellular calcium and induce ultrastructural changes in motoneurons. Synapse. 1995, 20: 185-199.PubMed
138.
Engelhardt JI, Siklos L, Appel SH: Altered calcium homeostasis and ultrastructure in motoneurons of mice caused by passively transferred anti-motoneuronal IgG. J Neuropathol Exp Neurol. 1997, 56: 21-39.PubMed
139.
Arsac C, Raymond C, Martin-Moutot N, Dargent B, Couraud F, Pouget J, Seagar M: Immunoassays fail to detect antibodies against neuronal calcium channels in amyotrophic lateral sclerosis serum. Ann Neurol. 1996, 40: 695-700.PubMed
140.
Gredal O, Witt MR, Dekermendjian K, Moller SE, Nielsen M: Cerebrospinal fluid from amyotrophic lateral sclerosis has no effect on intracellular free calcium in cultured cortical neurons. Mol Chem Neuropathol. 1996, 29: 141-152.PubMed
141.
Tang TS, Tu H, Chan EY, Maximov A, Wang Z, Wellington CL, Hayden MR, Bezprozvanny I: Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1. Neuron. 2003, 39: 227-239.PubMedCentralPubMed
142.
Dreses-Werringloer U, Lambert JC, Vingtdeux V, Zhao H, Vais H, Siebert A, Jain A, Koppel J, Rovelet-Lecrux A, Hannequin D, Pasquier F, Galimberti D, Scarpini E, Mann D, Lendon C, Campion D, Amouyel P, Davies P, Foskett JK, Campagne F, Marambaud P: A polymorphism in CALHM1 influences Ca2+ homeostasis, Abeta levels, and Alzheimer's disease risk. Cell. 2008, 133: 1149-1161.PubMedCentralPubMed
143.
van Es MA, Van Vught PW, Blauw HM, Franke L, Saris CG, Andersen PM, Bosch Van Den L, de Jong SW, van't Slot R, Birve A, Lemmens R, de Jong V, Baas F, Schelhaas HJ, Sleegers K, Van Broeckhoven C, Wokke JH, Wijmenga C, Robberecht W, Veldink JH, Ophoff RA, Berg van den LH: ITPR2 as a susceptibility gene in sporadic amyotrophic lateral sclerosis: a genome-wide association study. Lancet Neurol. 2007, 6: 869-877.PubMed
144.
145.
Watase K, Barrett CF, Miyazaki T, Ishiguro T, Ishikawa K, Hu Y, Unno T, Sun Y, Kasai S, Watanabe M, Gomez CM, Mizusawa H, Tsien RW, Zoghbi HY: Spinocerebellar ataxia type 6 knockin mice develop a progressive neuronal dysfunction with age-dependent accumulation of mutant CaV2.1 channels. Proc Natl Acad Sci USA. 2008, 105: 11987-11992.PubMedCentralPubMed
146.
Saegusa H, Wakamori M, Matsuda Y, Wang J, Mori Y, Zong S, Tanabe T: Properties of human Cav2.1 channel with a spinocerebellar ataxia type 6 mutation expressed in Purkinje cells. Mol Cell Neurosci. 2007, 34: 261-270.PubMed
147.
Matsuyama Z, Yanagisawa NK, Aoki Y, Black JL, Lennon VA, Mori Y, Imoto K, Inuzuka T: Polyglutamine repeats of spinocerebellar ataxia 6 impair the cell-death-preventing effect of CaV2.1 Ca2+ channel–loss-of-function cellular model of SCA6. Neurobiol Dis. 2004, 17: 198-204.PubMed
148.
Piedras-Renteria ES, Watase K, Harata N, Zhuchenko O, Zoghbi HY, Lee CC, Tsien RW: Increased expression of alpha 1A Ca2+ channel currents arising from expanded trinucleotide repeats in spinocerebellar ataxia type 6. J Neurosci. 2001, 21: 9185-9193.PubMed
149.
150.
Panov AV, Gutekunst CA, Leavitt BR, Hayden MR, Burke JR, Strittmatter WJ, Greenamyre JT: Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat Neurosci. 2002, 5: 731-736.PubMed
151.
Panov AV, Burke JR, Strittmatter WJ, Greenamyre JT: In vitro effects of polyglutamine tracts on Ca2+-dependent depolarization of rat and human mitochondria: relevance to Huntington's disease. Arch Biochem Biophys. 2003, 410: 1-6.PubMed
152.
Choo YS, Johnson GV, MacDonald M, Detloff PJ, Lesort M: Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. Hum Mol Genet. 2004, 13: 1407-1420.PubMed
153.
Calabresi P, Gubellini P, Picconi B, Centonze D, Pisani A, Bonsi P, Greengard P, Hipskind RA, Borrelli E, Bernardi G: Inhibition of mitochondrial complex II induces a long-term potentiation of NMDA-mediated synaptic excitation in the striatum requiring endogenous dopamine. J Neurosci. 2001, 21: 5110-5120.PubMed
154.
Swerdlow RH, Parks JK, Cassarino DS, Trimmer PA, Miller SW, Maguire DJ, Sheehan JP, Maguire RS, Pattee G, Juel VC, Phillips LH, Tuttle JB, Bennett JP, Davis RE, Parker WD: Mitochondria in sporadic amyotrophic lateral sclerosis. Exp Neurol. 1998, 153: 135-142.PubMed
155.
Borthwick GM, Johnson MA, Ince PG, Shaw PJ, Turnbull DM: Mitochondrial enzyme activity in amyotrophic lateral sclerosis: implications for the role of mitochondria in neuronal cell death. Ann Neurol. 1999, 46: 787-790.PubMed
156.
Beal MF: Mitochondria and the pathogenesis of ALS. Brain. 2000, 123 (Pt 7): 1291-1292.PubMed
157.
Damiano M, Starkov AA, Petri S, Kipiani K, Kiaei M, Mattiazzi M, Flint Beal M, Manfredi G: Neural mitochondrial Ca2+ capacity impairment precedes the onset of motor symptoms in G93A Cu/Zn-superoxide dismutase mutant mice. J Neurochem. 2006, 96: 1349-1361.PubMed
158.
Carriedo SG, Sensi SL, Yin HZ, Weiss JH: AMPA exposures induce mitochondrial Ca(2+) overload and ROS generation in spinal motor neurons in vitro. J Neurosci. 2000, 20: 240-250.PubMed
159.
Carri MT, Ferri A, Battistoni A, Famhy L, Gabbianelli R, Poccia F, Rotilio G: Expression of a Cu, Zn superoxide dismutase typical of familial amyotrophic lateral sclerosis induces mitochondrial alteration and increase of cytosolic Ca2+ concentration in transfected neuroblastoma SH-SY5Y cells. FEBS Lett. 1997, 414: 365-368.PubMed
160.
Kumar U, Dunlop DM, Richardson JS: Mitochondria from Alzheimer's fibroblasts show decreased uptake of calcium and increased sensitivity to free radicals. Life Sci. 1994, 54: 1855-1860.PubMed
161.
Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, Atwood CS, Johnson AB, Kress Y, Vinters HV, Tabaton M, Shimohama S, Cash AD, Siedlak SL, Harris PL, Jones PK, Petersen RB, Perry G, Smith MA: Mitochondrial abnormalities in Alzheimer's disease. J Neurosci. 2001, 21: 3017-3023.PubMed
162.
Caspersen C, Wang N, Yao J, Sosunov A, Chen X, Lustbader JW, Xu HW, Stern D, McKhann G, Yan SD: Mitochondrial Abeta: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease. Faseb J. 2005, 19: 2040-2041.PubMed
163.
Hansson Petersen CA, Alikhani N, Behbahani H, Wiehager B, Pavlov PF, Alafuzoff I, Leinonen V, Ito A, Winblad B, Glaser E, Ankarcrona M: The amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae. Proc Natl Acad Sci USA. 2008, 105: 13145-13150.PubMedCentralPubMed
164.
Sanz-Blasco S, Valero RA, Rodriguez-Crespo I, Villalobos C, Nunez L: Mitochondrial Ca2+ overload underlies Abeta oligomers neurotoxicity providing an unexpected mechanism of neuroprotection by NSAIDs. PLoS ONE. 2008, 3: e2718-PubMedCentralPubMed
165.
Canevari L, Abramov AY, Duchen MR: Toxicity of amyloid beta peptide: tales of calcium, mitochondria, and oxidative stress. Neurochem Res. 2004, 29: 637-650.PubMed
166.
Reddy PH, Beal MF: Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. Trends Mol Med. 2008, 14: 45-53.PubMedCentralPubMed
167.
Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD: Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem. 1990, 54: 823-827.PubMed
168.
Abou-Sleiman PM, Muqit MM, Wood NW: Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat Rev Neurosci. 2006, 7: 207-219.PubMed
169.
Chade AR, Kasten M, Tanner CM: Nongenetic causes of Parkinson's disease. J Neural Transm Suppl. 2006, 147-151.
170.
Langston JW, Ballard P, Tetrud JW, Irwin I: Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 1983, 219: 979-980.PubMed
171.
Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT: Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci. 2000, 3: 1301-1306.PubMed
172.
Khachaturian ZS: Calcium, membranes, aging, and Alzheimer's disease. Introduction and overview. Ann N Y Acad Sci. 1989, 568: 1-4.PubMed
173.
Kuchibhotla KV, Goldman ST, Lattarulo CR, Wu HY, Hyman BT, Bacskai BJ: Abeta plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks. Neuron. 2008, 59: 214-225.PubMedCentralPubMed
174.
Busche MA, Eichhoff G, Adelsberger H, Abramowski D, Wiederhold KH, Haass C, Staufenbiel M, Konnerth A, Garaschuk O: Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer's disease. Science. 2008, 321: 1686-1689.PubMed
175.
Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ: Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002, 416: 535-539.PubMed
176.
Freir DB, Costello DA, Herron CE: A beta 25–35-induced depression of long-term potentiation in area CA1 in vivo and in vitro is attenuated by verapamil. J Neurophysiol. 2003, 89: 3061-3069.PubMed
177.
Minogue AM, Schmid AW, Fogarty MP, Moore AC, Campbell VA, Herron CE, Lynch MA: Activation of the c-Jun N-terminal kinase signaling cascade mediates the effect of amyloid-beta on long term potentiation and cell death in hippocampus: a role for interleukin-1beta?. J Biol Chem. 2003, 278: 27971-27980.PubMed
178.
Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH: A specific amyloid-beta protein assembly in the brain impairs memory. Nature. 2006, 440: 352-357.PubMed
179.
Klyubin I, Betts V, Welzel AT, Blennow K, Zetterberg H, Wallin A, Lemere CA, Cullen WK, Peng Y, Wisniewski T, Selkoe DJ, Anwyl R, Walsh DM, Rowan MJ: Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J Neurosci. 2008, 28: 4231-4237.PubMedCentralPubMed
180.
Mattson MP, Cheng B, Culwell AR, Esch FS, Lieberburg I, Rydel RE: Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the beta-amyloid precursor protein. Neuron. 1993, 10: 243-254.PubMed
181.
MacManus A, Ramsden M, Murray M, Henderson Z, Pearson HA, Campbell VA: Enhancement of (45)Ca(2+) influx and voltage-dependent Ca(2+) channel activity by beta-amyloid-(1–40) in rat cortical synaptosomes and cultured cortical neurons. Modulation by the proinflammatory cytokine interleukin-1beta. J Biol Chem. 2000, 275: 4713-4718.PubMed
182.
Zhao D, Watson JB, Xie CW: Amyloid beta prevents activation of calcium/calmodulin-dependent protein kinase II and AMPA receptor phosphorylation during hippocampal long-term potentiation. J Neurophysiol. 2004, 92: 2853-2858.PubMed
183.
Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ: Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med. 2008, 14: 837-842.PubMedCentralPubMed
184.
Mirzabekov TA, Lin MC, Kagan BL: Pore formation by the cytotoxic islet amyloid peptide amylin. J Biol Chem. 1996, 271: 1988-1992.PubMed
185.
Danzer KM, Haasen D, Karow AR, Moussaud S, Habeck M, Giese A, Kretzschmar H, Hengerer B, Kostka M: Different species of alpha-synuclein oligomers induce calcium influx and seeding. J Neurosci. 2007, 27: 9220-9232.PubMed
186.
Quist A, Doudevski I, Lin H, Azimova R, Ng D, Frangione B, Kagan B, Ghiso J, Lal R: Amyloid ion channels: a common structural link for protein-misfolding disease. Proc Natl Acad Sci USA. 2005, 102: 10427-10432.PubMedCentralPubMed
187.
Tsigelny IF, Crews L, Desplats P, Shaked GM, Sharikov Y, Mizuno H, Spencer B, Rockenstein E, Trejo M, Platoshyn O, Yuan JX, Masliah E: Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases. PLoS ONE. 2008, 3: e3135-PubMedCentralPubMed
188.
Davies P: A very incomplete comprehensive theory of Alzheimer's disease. Ann N Y Acad Sci. 2000, 924: 8-16.PubMed
189.
Litersky JM, Johnson GV, Jakes R, Goedert M, Lee M, Seubert P: Tau protein is phosphorylated by cyclic AMP-dependent protein kinase and calcium/calmodulin-dependent protein kinase II within its microtubule-binding domains at Ser-262 and Ser-356. Biochem J. 1996, 316 (Pt 2): 655-660.PubMedCentralPubMed
190.
Baumann K, Mandelkow EM, Biernat J, Piwnica-Worms H, Mandelkow E: Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5. FEBS Lett. 1993, 336: 417-424.PubMed
191.
Patrick GN, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, Tsai LH: Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature. 1999, 402: 615-622.PubMed
192.
Kusakawa G, Saito T, Onuki R, Ishiguro K, Kishimoto T, Hisanaga S: Calpain-dependent proteolytic cleavage of the p35 cyclin-dependent kinase 5 activator to p25. J Biol Chem. 2000, 275: 17166-17172.PubMed
193.
Fleming LM, Johnson GV: Modulation of the phosphorylation state of tau in situ: the roles of calcium and cyclic AMP. Biochem J. 1995, 309 (Pt 1): 41-47.PubMedCentralPubMed
194.
Johnson GV, Jope RS, Binder LI: Proteolysis of tau by calpain. Biochem Biophys Res Commun. 1989, 163: 1505-1511.PubMed
195.
Trinchese F, Fa M, Liu S, Zhang H, Hidalgo A, Schmidt SD, Yamaguchi H, Yoshii N, Mathews PM, Nixon RA, Arancio O: Inhibition of calpains improves memory and synaptic transmission in a mouse model of Alzheimer disease. J Clin Invest. 2008, 118: 2796-2807.PubMedCentralPubMed
196.
Sato S, Xu J, Okuyama S, Martinez LB, Walsh SM, Jacobsen MT, Swan RJ, Schlautman JD, Ciborowski P, Ikezu T: Spatial learning impairment, enhanced CDK5/p35 activity, and downregulation of NMDA receptor expression in transgenic mice expressing tau-tubulin kinase 1. J Neurosci. 2008, 28: 14511-14521.PubMed
197.
Wilquet V, De Strooper B: Amyloid-beta precursor protein processing in neurodegeneration. Curr Opin Neurobiol. 2004, 14: 582-588.PubMed
198.
Marambaud P, Robakis NK: Genetic and molecular aspects of Alzheimer's disease shed light on new mechanisms of transcriptional regulation. Genes Brain Behav. 2005, 4: 134-146.PubMed
199.
Querfurth HW, Selkoe DJ: Calcium ionophore increases amyloid beta peptide production by cultured cells. Biochemistry. 1994, 33: 4550-4561.PubMed
200.
Pierrot N, Ghisdal P, Caumont AS, Octave JN: Intraneuronal amyloid-beta1–42 production triggered by sustained increase of cytosolic calcium concentration induces neuronal death. J Neurochem. 2004, 88: 1140-1150.PubMed
201.
Buxbaum JD, Ruefli AA, Parker CA, Cypess AM, Greengard P: Calcium regulates processing of the Alzheimer amyloid protein precursor in a protein kinase C-independent manner. Proc Natl Acad Sci USA. 1994, 91: 4489-4493.PubMedCentralPubMed
202.
Petryniak MA, Wurtman RJ, Slack BE: Elevated intracellular calcium concentration increases secretory processing of the amyloid precursor protein by a tyrosine phosphorylation-dependent mechanism. Biochem J. 1996, 320 (Pt 3): 957-963.PubMedCentralPubMed
203.
Mattson MP: Secreted forms of beta-amyloid precursor protein modulate dendrite outgrowth and calcium responses to glutamate in cultured embryonic hippocampal neurons. J Neurobiol. 1994, 25: 439-450.PubMed
204.
Kim HS, Lee JH, Suh YH: C-terminal fragment of Alzheimer's amyloid precursor protein inhibits sodium/calcium exchanger activity in SK-N-SH cell. Neuroreport. 1999, 10: 113-116.PubMed
205.
Kim HS, Park CH, Cha SH, Lee JH, Lee S, Kim Y, Rah JC, Jeong SJ, Suh YH: Carboxyl-terminal fragment of Alzheimer's APP destabilizes calcium homeostasis and renders neuronal cells vulnerable to excitotoxicity. Faseb J. 2000, 14: 1508-1517.PubMed
206.
Cullen WK, Suh YH, Anwyl R, Rowan MJ: Block of LTP in rat hippocampus in vivo by beta-amyloid precursor protein fragments. Neuroreport. 1997, 8: 3213-3217.PubMed
207.
Nalbantoglu J, Tirado-Santiago G, Lahsaini A, Poirier J, Goncalves O, Verge G, Momoli F, Welner SA, Massicotte G, Julien JP, Shapiro ML: Impaired learning and LTP in mice expressing the carboxy terminus of the Alzheimer amyloid precursor protein. Nature. 1997, 387: 500-505.PubMed
208.
Leissring MA, Murphy MP, Mead TR, Akbari Y, Sugarman MC, Jannatipour M, Anliker B, Muller U, Saftig P, De Strooper B, Wolfe MS, Golde TE, LaFerla FM: A physiologic signaling role for the gamma -secretase-derived intracellular fragment of APP. Proc Natl Acad Sci USA. 2002, 99: 4697-4702.PubMedCentralPubMed
209.
Tu H, Nelson O, Bezprozvanny A, Wang Z, Lee SF, Hao YH, Serneels L, De Strooper B, Yu G, Bezprozvanny I: Presenilins form ER Ca2+ leak channels, a function disrupted by familial Alzheimer's disease-linked mutations. Cell. 2006, 126: 981-993.PubMedCentralPubMed
210.
Nelson O, Tu H, Lei T, Bentahir M, de Strooper B, Bezprozvanny I: Familial Alzheimer disease-linked mutations specifically disrupt Ca2+ leak function of presenilin 1. J Clin Invest. 2007, 117: 1230-1239.PubMedCentralPubMed
211.
Cheung KH, Shineman D, Muller M, Cardenas C, Mei L, Yang J, Tomita T, Iwatsubo T, Lee VM, Foskett JK: Mechanism of Ca2+ disruption in Alzheimer's disease by presenilin regulation of InsP3 receptor channel gating. Neuron. 2008, 58: 871-883.PubMedCentralPubMed
212.
Rybalchenko V, Hwang SY, Rybalchenko N, Koulen P: The cytosolic N-terminus of presenilin-1 potentiates mouse ryanodine receptor single channel activity. Int J Biochem Cell Biol. 2008, 40: 84-97.PubMed
213.
Green KN, Demuro A, Akbari Y, Hitt BD, Smith IF, Parker I, LaFerla FM: SERCA pump activity is physiologically regulated by presenilin and regulates amyloid beta production. J Cell Biol. 2008, 181: 1107-1116.PubMedCentralPubMed
214.
Dermaut B, Kumar-Singh S, Rademakers R, Theuns J, Cruts M, Van Broeckhoven C: Tau is central in the genetic Alzheimer-frontotemporal dementia spectrum. Trends Genet. 2005, 21: 664-672.PubMed
215.
Lee VM, Trojanowski JQ: Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery. Neuron. 2006, 52: 33-38.PubMed
216.
Marambaud P, Campagne F, Dreses-Werringloer U, Lambert J-C, Koppel J, Zhao H, Pasquier F, Amouyel P, Davies P: The calcium homeostasis modulator CALHM1 is genetically associated with Alzheimer disease. Society for Neuroscience Online. 2007, Program No.795.24/N16. Neuroscience Meeting Planner. San Diego, CA,
Metadata
Title
Calcium signaling in neurodegeneration
Authors
Philippe Marambaud
Ute Dreses-Werringloer
Valérie Vingtdeux
Publication date
01-12-2009
Publisher
BioMed Central
Published in
Molecular Neurodegeneration / Issue 1/2009
Electronic ISSN: 1750-1326
DOI
https://doi.org/10.1186/1750-1326-4-20

Other articles of this Issue 1/2009

Molecular Neurodegeneration 1/2009 Go to the issue

Research article

Emerging role of LRRK2 in human neural progenitor cell cycle progression, survival and differentiation

Methodology

Independent component analysis of Alzheimer's DNA microarray gene expression data

Research article

Ectopic localization of FOXO3a protein in Lewy bodies in Lewy body dementia and Parkinson's disease

Research article

Effects of chronic low dose rotenone treatment on human microglial cells

Research article

LRP1 shedding in human brain: roles of ADAM10 and ADAM17

Research article

GSK-3β phosphorylation of functionally distinct tau isoforms has differential, but mild effects